drugset / Trial / NCT02991209

Study of Testosterone vs Placebo in Testicular Cancer Survivors

NCT02991209

Phase 2/3 Completed 69 enrolled Mikkel Bandak
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The overall purpose of the study is to evaluate the effect of 12 months testosterone replacement therapy in testicular cancer survivors with mild Leydig Cell Insufficiency in order to reduce the risk of cardiovascular disease. The primary study objective is to evaluate changes in insulin sensitivity. The secondary study objective is to evaluate changes in the prevalence of metabolic syndrome, body composition, systemic inflammation and symptoms of testosterone deficiency.

Timeline

Start
2016-11
Primary completion
2019-06
Completion
2019-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 40 mg